

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. FOSTER ET AL.  
NOT YET KNOWN  
APPLICATION NO.  
PCT/PTC 21 MAR 2005  
FILING DATE  
Herewith

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	197 39 693	3/11/99	DE			<input type="checkbox"/>	<input type="checkbox"/>
	AN	1 002 792	5/24/00	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	02/072019	9/19/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	02/18395	3/7/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Brinkman et al., "The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors", J. Biolog. Chem., Vol. 277, No. 24, pp. 21453-21457 (2002).
AS	Brinkman et al., "FTY720: Targeting G-Protein-Coupled Receptors for Sphingosine 1-Phosphate in Transplantation and Autoimmunity", Current Opinion in Immunology, Vol. 14, No. 5, pp. 569-575 (2002).
AT	Hoshino et al., "FTY720, a Novel Immunosuppressant, Shows a Synergistic Effect in Combination with FK 506 in Rat Allograft Models", Transplantation Proceedings, Vol. 31, No. 1-2, pp. 1224-1226 (1999).
AU	Moser, "Clinical and Therapeutic Aspects of Adrenoleukodystrophy and Adrenomyeloneuropathy", J. Neuropathology and Experimental Neurology, Vol. 54, No. 5, pp. 740-745 (1995).

EXAMINER

/Sahar Javanmard/

DATE CONSIDERED

06/19/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.